Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/33376
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
DC FieldValueLanguage
dc.contributor.authorSkolnick, Phil-
dc.contributor.authorPopik, Piotr-
dc.contributor.authorTrullas, Ramón-
dc.date.accessioned2011-03-14T11:32:24Z-
dc.date.available2011-03-14T11:32:24Z-
dc.date.issued2009-11-
dc.identifier.citationTrends in Pharmacological Sciences 30(11): 563-569 (2009)es_ES
dc.identifier.issn0165-6147-
dc.identifier.urihttp://hdl.handle.net/10261/33376-
dc.descriptionEl pdf del artículo es el manuscrito de autor.-
dc.description.abstractDepression is a chronic recurring illness that affects more than 120 million people worldwide. Drugs increasing the synaptic availability of serotonin and norepinephrine (biogenic amine-based agents) have been used to treat depression for more than 50 years. However, significant symptom improvement requires ≥2–4 weeks of treatment and a first course of therapy provides symptom relief to only 60–65% of patients. Roche and Evotec recently announced plans to develop N-methyl-D-aspartate (NMDA) receptor antagonists targeting the NR2B subtype for treatment-resistant depression. This announcement closely follows a report that another NR2B antagonist, traxoprodil (CP 101 606), has antidepressant effects in patients unresponsive to a serotonin selective reuptake inhibitor, as well as reports of rapid and sustained antidepressant effects following a single injection of the NMDA antagonist ketamine. Here we describe evidence that glutamate-based therapies might represent an effective alternative to biogenic-amine-based agents for depression and provide perspectives on the development of these agents.es_ES
dc.description.sponsorshipR.T. is supported by the Ministerio Ciencia e Innovación of Spain, grant SAF2008-03514 and by the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED).-
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsopenAccesses_ES
dc.titleGlutamate-based antidepressants: 20 years ones_ES
dc.typeartículoes_ES
dc.identifier.doi10.1016/j.tips.2009.09.002-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1016/j.tips.2009.09.002-
dc.identifier.e-issn1873-3735-
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.openairetypeartículo-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Collections:(IIBB) Artículos
Files in This Item:
File Description SizeFormat
Glutamate-based.pdf588,96 kBAdobe PDFThumbnail
View/Open
Show simple item record

SCOPUSTM   
Citations

331
checked on Jun 29, 2022

WEB OF SCIENCETM
Citations

301
checked on Jul 2, 2022

Page view(s)

361
checked on Jul 3, 2022

Download(s)

624
checked on Jul 3, 2022

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.